Table 1. In Vitro Cytotoxicity of Eugenol Derivatives (5–17)^a.

	half maximal inhibitory concentration (IC50, μM)
compounds	breast MCF7	ovarian SKOV3	prostate PC3
5	25.74 ± 3.52	15.73 ± 3.43	11.18 ± 2.72
6	16.33 ± 2.80	41.06 ± 5.27	16.98± 1.08
7	45.89 ± 3.80	65.4 ± 2.81	24.30 ± 1.53
8	10.74 ± 2.76	70.01 ± 2.42	29.96 ± 0.91
9	2.87±0.56	3.36±0.80	2.09±0.68
10	45.01 ± 2.92	8.74 ± 1.06	7.07 ± 3.90
11	15.21 ± 3.77	26.33 ± 3.09	51.09 ± 2.92
12	6.54 ± 1.42	14.09 ± 2.17	16.72 ± 4.10
13	38.92 ± 3.20	61.09 ± 3.84	20.27 ± 0.75
14	172.86 ± 1.36	181.46 ± 3.58	124.90 ± 0.36
15	9.55 ± 0.71	16.86 ± 1.64	10.01 ± 0.99
16	33.18 ± 2.04	19.54 ± 2.48	26.65 ± 0.86
17	1.71±0.95	1.84±0.27	1.1±0.07
doxorubicin	1.74 ± 0.34	2.88 ± 0.68	2.61 ± 0.23

^aData represent the mean values ± standard deviation of three independent experiments.